


## GOAT ANTI-LRRK2 / PARK8 (NEAR C TERMINUS) ANTIBODY

SKU: EB06550



## SPECIFICATIONS

**Formulation** Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

**Unit Size** 100 µg

**Storage Instructions** Aliquot and store at -20°C. Minimize freezing and thawing.

**Synonym /**

**Alias** Parkinson disease (autosomal dominant) 8|dardarin|leucine-rich repeat kinase

**Names**

2|DKFZp434H2111|FLJ45829|ROCO2|PARK8|LRRK2

**Usage**

**Summary** **Immunofluorescence:** Strong expression of the protein seen in the vesicles of A431 cells and in the vesicles and nuclei of A549 cells. Recommended concentration: 10µg/ml.

**Accession ID**

NP\_940980.3

**Blocking Peptide**

EBP06550

<b>Immunogen</b>	Peptide with sequence CELAEKMRRTSV, from the internal region (near the C Terminus) of the protein sequence according to NP_940980.3.
<b>Peptide Sequence</b>	CELAEKMRRTSV
<b>Purification Method</b>	Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
<b>Shipping Instructions</b>	Refrigerated
<b>Predicted Species</b>	Human
<b>Reactive Species</b>	Human
<b>Human Gene ID</b>	120892
<b>Product Grade</b>	<a href="https://prod-vector-labs-pimcore-assets.s3.us-east-1.amazonaws.com/assets/products/image/elite_medium.png">https://prod-vector-labs-pimcore-assets.s3.us-east-1.amazonaws.com/assets/products/image/elite_medium.png</a>
<b>ELISA Detection Limit</b>	Antibody detection limit dilution 1:128000.
<b>Western Blot</b>	Not yet tested - our routine western blotting protocol does not allow for the detection of proteins >250kDa (calculated MWt of approx. 286kDa according to NP_940980.3). However, customer testing has shown bands at >250kDa + 140kDa, which has been observed by other commercial sources of LRRK2 antibodies.
<b>Application Type</b>	Pep-ELISA, IF

## SELECTED REFERENCES

[{"pmid": 19640926, "intro": "**This antibody (previous batch) has been successfully used in IEM:**", "title": "LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model.", "author": "Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge O, Wade-Martins R.", "journal": "Hum Mol Genet. 2009 Nov 1;18(21):4022-34."}, {"pmid": 36219522, "intro": "**This antibody has been successfully used in the following paper:**", "title": "LRRK2 expression in normal and pathologic human gut and in rodent enteric neural cell lines.", "author": "Adrien De Guilhem De Lataillade, Martial Caillaud, Thibauld Oullier, Philippe Naveilhan, Carolina Pellegrini, Eduardo Tolosa, Michel Neunlist, Malvyne Rolli-Derkinderen, Ellen Gelpi, Pascal Derkinderen", "journal": "J Neurochem. 2023 Jan;164(2):193-209."}, {"pmid": 17971075, "intro": "**This antibody (previous batch) has been successfully used in WB and IHC on Human:**", "title": "LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.", "author": "Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R.", "journal": "Neuropathol Appl Neurobiol. 2007 Oct 26."}, {"pmid": 21696411, "intro": "**This antibody (previous batch) has been successfully used in ICC on Human:**", "title": "LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: A morphological and quantitative study.", "author": "Sharma S, Bandopadhyay R, Lashley T,}

Renton AE, Kingsbury AE, Kumaran R, Kallis C, Vilariño-Güell C, O'Sullivan SS, Lees AJ, Revesz T, Wood NW, Holton JL.", "journal": "Neuropathol Appl Neurobiol. 2011 Jun 23."}]

## DOCUMENTS

- [Data Sheet](#)

## GALLERY IMAGES

